Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1997-09-29
2000-02-15
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
424 7801, 424439, 426 2, 426615, 514 54, 514867, 514911, 536 2, A61K 3578, A61K 4700, C08B 3706
Patent
active
060249595
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a novel modified plant fibre preparation with a curative and prophylactic effect on acute infectious diarrhoea and chronic and subchronic, partially symptomless progressing diseases, including infections in the gastrointestinal tract.
Furthermore, the same preparation has surprisingly been found to have a curative effect on gastric ulcers.
Besides, the invention, which is a further development of DK patent No. 153,442 owned by the inventor, implies a substantial simplification of the manufacturing technique compared to that of the above DK patent.
It has long been known that plant fibres in general and in particular fibres having a high content of pectic substances (polygalacturonic acid complexes) exhibit a favourable effect on infectious and non-infectious diarrhoea.
Whereas the use of pectic substances previously rested on a purely empirical basis both within the popular medicine and in a more pharmaceutical-industrial connection, their effects today may be described as effects intervening in some of the pathophysiological mechanisms determining the development of the most widespread types of infectious diarrhoea.
Thus, numerous scientific investigations have demonstrated that the most widespread types of infectious diarrhoea, such as the enterotoxic Escherichia coli diarrhoea, and some virus-related types of diarrhoea are caused by disorders in the enzyme-related mechanisms which via the epithelium of the small intestine maintain a balance prevailing between liquid absorption and liquid secretion.
The disorder in the enteral liquid regulation caused by bacteria or virus infection typically results in a drastic reduction in the liquid absorption simultaneously with an excessive increase in the liquid secretion from the intestinal wall out into the bowel contents, which as a result of various self-increasing effects causes the development of diarrhoea.
It is generally known that these basic enzyme-related mechanisms of the diarrhoeic pathogenesis all require a prior adhesion of the pathogenic microorganisms to the outer cell layer of the intestinal epithelium, upon which the adhesion is quickly followed by a heavy bacterial proliferation. The adhesion followed by propagation, referred to as bacterial colonisation, is thus the first step of the diarrhoea-producing mechanisms described above.
As far as the pathogenesis of virus infections is concerned, it may be stated that the dysregulation of the liquid balance and the diarrhoea resulting thereof are caused by a damage of the epithelial cells associated with the virus infection.
Based on the above diarrhoeic pathogenesis, the latest patent literature contains descriptions of diarrhoeic agents which aim at intervening in the initial mechanisms decisive for the development of diarrhoea, the attention being particularly paid to the importance of hydrophobic/hydrophobic bonds, the so-called "like-like" interactions", e.g. for the development of Escherichia coli infections.
In order to intervene in some of the forces applying to the bacterial colonisation, EP patent publication No. 0 021 230 describes an agent comprising one or more polymeric carbohydrates or sugars having a hydrophobic group and a molecular weight which is sufficiently high to prevent them from penetrating a cellular membrane, and a physiologically acceptable inorganic material having a hydrophobic surface layer.
The purpose of using said combination of a polymer having a hydrophobic group and an inorganic material having a hydrophobic surface layer is to attract the pathogenic bacteria and to cause these to adhere to the polymer and the inorganic material rather than to the cell tissue, e.g. the intestinal cell tissue. The prior art agent does not contain pectin and the introduction of the hydrophobic group on the polymer is based on a chemical reaction, viz. an etherification, esterification or amidation.
DK patent No. 153 442 B belonging to the Applicant describes an agent based on a pectinaceous material for the treatment and prevention of diarrhoea in hu
REFERENCES:
patent: 4076717 (1978-02-01), Kreider
patent: 4162306 (1979-07-01), Laves
patent: 4321263 (1982-03-01), Powell et al.
patent: 4551331 (1985-11-01), Rudin
patent: 4867979 (1989-09-01), Sheth et al.
patent: 4950655 (1990-08-01), Bachmann
patent: 4999200 (1991-03-01), Casillan
patent: 5258181 (1993-11-01), Cregier et al.
patent: 5462742 (1995-10-01), Bogentoft et al.
Lankford , Jr. Leon B.
Tate Christopher R.
LandOfFree
Pharmaceutical composition containing pectin and a phospholipid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition containing pectin and a phospholipid , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition containing pectin and a phospholipid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1903571